{
    "clinical_study": {
        "@rank": "72080", 
        "acronym": "RITULUP", 
        "arm_group": [
            {
                "arm_group_label": "Rituximab (1 cycle)", 
                "arm_group_type": "Active Comparator", 
                "description": "1 cycle of Rituximab (4 i.v. infusions):\nDay 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2"
            }, 
            {
                "arm_group_label": "Rituximab (2 cycles)", 
                "arm_group_type": "Experimental", 
                "description": "A second cycle of Rituximab\nFirst cycle of Rituximab (4 i.v. infusions):\nDay 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2\nSecond cycle of Rituximab (4 i.v. infusions, 6 months later)"
            }
        ], 
        "brief_summary": {
            "textblock": "Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus\n      Nephropathy Resistant to Conventional Treatments"
        }, 
        "brief_title": "Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Lupus Nephritis", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Lupus Nephritis", 
                "Nephritis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Randomized, open, controlled, multicenter, clinical trial in patients with lupus nephritis\n      previously treated with cyclophosphamide and mycophenolate. These patient can not have\n      received Rituximab in the previous year. The number of patients estimated to reach\n      statistical significance is 18 in each arm, a total sample size of 32 patients is needed.\n\n      The hypothesis is that the alternative procedure (a second cycle of Rituximab)will reduce\n      the relapse rate of lupus nephritis and the consequent deterioration of renal function.\n      Besides it will reduce health care expenses(hospitalization, medication, hemodialysis and\n      renal transplantation)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Both men and women between 18 and 70 years.\n\n          -  Patient  with active lupus nephritis,  previously treated with cyclophosphamide and\n             mycophenolate (sodium or mofetil), who have not received rituximab in the previous\n             year.\n\n          -  Women in childbearing age must have a pregnancy test in serum or urine negative and\n             should use a contraceptive method suitable since at least 14 days prior to their\n             inclusion in the study and up to 6 months after the last dose of the medication of\n             the test.\n\n          -  Informed consent form signed.\n\n        Exclusion Criteria:\n\n          -  Patients treated with rituximab in the previous years\n\n          -  Active/sepsis serious infections\n\n          -  Renal biopsy showing interstitial fibrosis and/or glomerular over 75%.\n\n          -  Known neoplasia\n\n          -  Heart failure with  III/IV functional class\n\n          -  Pregnancy\n\n          -  Nursing\n\n          -  Known anaphylaxis to the product\n\n          -  History of hepatitis c\n\n          -  History of tuberculosis\n\n          -  Cardiovascular disease or uncontrolled hypertension\n\n          -  Chronic hepatitis B\n\n          -  Serious Cytopenia (granulocytes < 500/mm3, further < 10000/mm3)\n\n          -  Immunodeficiency (CVI, immunoglobulins deficiency)\n\n          -  Infection with HIV"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01765842", 
            "org_study_id": "RITULUP"
        }, 
        "intervention": {
            "arm_group_label": [
                "Rituximab (1 cycle)", 
                "Rituximab (2 cycles)"
            ], 
            "description": "Only one cycle of rituximab will be administered in this arm.", 
            "intervention_name": "Rituximab", 
            "intervention_type": "Biological", 
            "other_name": "Mabthera"
        }, 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Lupus Nephritis", 
            "remission", 
            "immunosuppressive treatment"
        ], 
        "lastchanged_date": "January 8, 2013", 
        "location": [
            {
                "contact": {
                    "email": "nortego@gmail.com", 
                    "last_name": "Norberto Ortego Centeno, MD, PhD", 
                    "phone": "0034958023559"
                }, 
                "facility": {
                    "address": {
                        "city": "Granada", 
                        "country": "Spain", 
                        "zip": "18012"
                    }, 
                    "name": "San Cecilio Hospital"
                }, 
                "investigator": {
                    "last_name": "Norberto Ortego Centeno, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "imsuarez@telefonica.net", 
                    "last_name": "Ignacio Mart\u00edn Suarez, MD, PhD", 
                    "phone": "0034959016131"
                }, 
                "facility": {
                    "address": {
                        "city": "Huelva", 
                        "country": "Spain", 
                        "zip": "21005"
                    }, 
                    "name": "Juan Ram\u00f3n Jim\u00e9nez Hospital"
                }, 
                "investigator": {
                    "last_name": "Ignacio Mart\u00edn Suarez, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "ederamongm2@gmail.com", 
                    "last_name": "Enrique Ram\u00f3n Garrido, MD, PhD", 
                    "phone": "0034951290013"
                }, 
                "facility": {
                    "address": {
                        "city": "M\u00e1laga", 
                        "country": "Spain", 
                        "zip": "29010"
                    }, 
                    "name": "Carlos Haya Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Enrique Ram\u00f3n Garrido, MD, Phd", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Enrique Ram\u00f3n Garrido, MD, PhD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "claram.rosso.sspa@juntadeandalucia.es", 
                    "last_name": "Clara M. Rosso Fern\u00e1ndez, MD", 
                    "phone": "0034955013414"
                }, 
                "facility": {
                    "address": {
                        "city": "Seville", 
                        "country": "Spain", 
                        "zip": "41013"
                    }, 
                    "name": "Virgen del Roc\u00edo, Hospital"
                }, 
                "investigator": {
                    "last_name": "Mar\u00eda Jes\u00fas Castillo Palma, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy Resistant to Conventional Treatments.", 
        "overall_contact": {
            "email": "MAJECA@telefonica.net", 
            "last_name": "Mar\u00eda Jes\u00fas Castillo Palma, MD, PhD", 
            "phone": "00349550134"
        }, 
        "overall_contact_backup": {
            "email": "claram.rosso.sspa@juntadeandalucia.es", 
            "last_name": "Clara M. Rosso Fern\u00e1ndez, MD", 
            "phone": "00349550134"
        }, 
        "overall_official": {
            "affiliation": "Virgen del Roc\u00edo Hospital", 
            "last_name": "Mar\u00eda Jes\u00fas Castillo Palma, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Complete response defined as:\nGlomerular Filtration Rate (GFR)\u2265 60, 73 m2 (or decline to baseline or\n\u00b1 15% of baseline in those with GFR <60 ml/min/1, 73m2).\nProteinuria \u2264 0.5 g/24 hours.\nInactive urine sediment (red cells, white cells, red cell casts according to local laboratory ranges).\nSerum albumin> 3 g / dl\nPartial response defined as:\nIn patients with proteinuria \u2265 3.5 gr/24 h , decreased proteinuria <3.5 gr/24 hours.\nIn patients with baseline proteinuria <3.5 gr/24 hours, reduced proteinuria> 50% of baseline.\nIn both situations, stabilization (\u00b1 25%) or reduce of the Glomerular Filtration Rate.", 
            "measure": "Rate of complete or partial response in lupus nephritis", 
            "safety_issue": "No", 
            "time_frame": "Assessment  at 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01765842"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Proportion of patients achieving a stabilization of renal function (Glomerular filtration rate of \u00b1 25% over baseline or serum creatinine within normal range)", 
                "measure": "Renal function", 
                "safety_issue": "Yes", 
                "time_frame": "24 months of follow-up"
            }, 
            {
                "description": "Incidence of adverse events, serious adverse events and adverse events that led to the interruption of the study.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "24 months of follow-up"
            }, 
            {
                "description": "Need for immunosuppressive treatment added to the experimental pattern:\n- Mycophenolate\n- Azathioprine\n- Methotrexate", 
                "measure": "Rescue medication", 
                "safety_issue": "Yes", 
                "time_frame": "24 months of follow-up"
            }, 
            {
                "description": "Improvements in Selena-SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) score results", 
                "measure": "Efficacy", 
                "safety_issue": "Yes", 
                "time_frame": "24 months of follow-up"
            }
        ], 
        "source": "Fundaci\u00f3n P\u00fablica Andaluza Progreso y Salud", 
        "sponsors": {
            "collaborator": {
                "agency": "Ministry of Health, Spain", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Fundaci\u00f3n P\u00fablica Andaluza Progreso y Salud", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}